Edwards Lifesciences (NYSE:EW) VP Sells $87,002.22 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $81.82 on Friday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company’s 50 day moving average price is $82.41 and its two-hundred day moving average price is $81.58. The stock has a market cap of $47.52 billion, a P/E ratio of 44.71, a P/E/G ratio of 2.21 and a beta of 0.93. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EW. World Investment Advisors increased its holdings in Edwards Lifesciences by 10.7% in the 4th quarter. World Investment Advisors now owns 39,986 shares of the medical research company’s stock worth $3,409,000 after acquiring an additional 3,877 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in Edwards Lifesciences by 20.7% during the fourth quarter. Corient Private Wealth LLC now owns 100,051 shares of the medical research company’s stock valued at $8,547,000 after purchasing an additional 17,144 shares during the last quarter. Hsbc Holdings PLC boosted its position in Edwards Lifesciences by 0.7% during the fourth quarter. Hsbc Holdings PLC now owns 2,148,974 shares of the medical research company’s stock worth $183,188,000 after purchasing an additional 15,577 shares during the period. Pure Financial Advisors LLC bought a new position in Edwards Lifesciences during the fourth quarter worth about $217,000. Finally, Rehmann Capital Advisory Group increased its stake in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Wells Fargo & Company raised their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. BTIG Research restated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.